Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial

Helicobacter
Hassan Ali MetanatZohreh Bari

Abstract

Helicobacter pylori (H. pylori) eradication has always been a concern. In our previous study, 14-day hybrid regimen showed ideal results. Based on these findings, we decided to compare the efficacy of 10- and 14-day hybrid regimens for H. pylori eradication. Two hundred and seventy patients with peptic ulcer disease and H. pylori infection were enrolled in the study. One hundred and thirty-four patients received 10-day hybrid regimen (PACT-10): pantoprazole, 40 mg, and amoxicillin, 1 g, both twice daily for 10 days; plus clarithromycin, 500 mg, and tinidazole, 500 mg, both twice daily just during the last 5 days. One hundred and thirty-six patients received 14-day hybrid regimen (PACT-14): pantoprazole, 40 mg, and amoxicillin, 1 g, both twice a day for 14 days; plus clarithromycin, 500 mg, and tinidazole, 500 mg, both twice daily just for the last 7 days. Eight weeks after treatment, (14) C-urea breath test was performed to evaluate H. pylori eradication. Two hundred and fifty patients (124 patients in PACT-10 and 126 patients in PACT-14 regimens) completed the study. The intention-to-treat eradication rates were 77.6% (95% confidence interval (CI): 70.6-84.6%) and 86% (95% CI: 80-92%) for the two regimens, respectively (p = .1...Continue Reading

References

Aug 3, 2007·Helicobacter·David Y GrahamYoshio Yamaoka
Nov 16, 2010·Helicobacter·Amin Talebi Bezmin AbadiLutz Wolfram
Jul 6, 2011·Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association·Leila ShokrzadehMohammad R Zali
Mar 13, 2012·World Journal of Gastrointestinal Pharmacology and Therapeutics·Ayako YanaiShin Maeda
May 15, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Morteza MilaniYaeghob Sharifi
Aug 11, 2012·European Journal of Internal Medicine·Angelo ZulloDino Vaira
Sep 14, 2012·Helicobacter·Haim ShmuelyYaron Niv
Sep 27, 2012·Current Opinion in Gastroenterology·Peter MalfertheinerJan Bornschein
Oct 2, 2012·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Angelo ZulloDino Vaira
Jun 12, 2013·Clinics and Research in Hepatology and Gastroenterology·Angelo ZulloPiero Portincasa
Sep 18, 2013·Helicobacter·Anthony O'ConnorColm O'Morain
Jan 15, 2014·Expert Review of Gastroenterology & Hepatology·Jeng-Yih WuDavid Y Graham
Feb 28, 2014·World Journal of Gastroenterology : WJG·Tajana Filipec Kanizaj, Nino Kunac
Jun 24, 2014·Journal of Gastroenterology and Hepatology·Dong Hyun OhHyun Chae Jung

❮ Previous
Next ❯

Citations

Sep 4, 2015·Expert Opinion on Pharmacotherapy·Sotirios D GeorgopoulosStylianos Karatapanis
Apr 12, 2016·Chinese Medical Journal·Zhi-Qiang SongLi-Ya Zhou
Sep 16, 2015·Helicobacter·Anthony O'ConnorSpiros Ladas
Jun 28, 2016·Gastroenterología y hepatología·Javier P GisbertAdrián G McNicholl
Aug 18, 2016·Helicobacter·Anthony O'ConnorColm O'Morain
Oct 5, 2016·Middle East Journal of Digestive Diseases·Saman AlhooeiZohreh Bari
Apr 10, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Muhammad Miftahussurur, Yoshio Yamaoka
Jul 14, 2020·Journal of Chemotherapy·Samin AlihosseiniHamed Ebrahimzadeh Leylabadlo
Apr 24, 2018·Middle East Journal of Digestive Diseases·Hafez FakheriZohreh Bari
Jun 29, 2018·Journal of Pathogens·Amin Talebi Bezmin Abadi
May 25, 2016·World Journal of Gastroenterology : WJG·Zhi-Qiang Song, Li-Ya Zhou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.